Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Prostatic Neoplasms × abiraterone × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 37 INDUSTRY 29 OTHER_GOV 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3 Zoledronic Acid 3 enzalutamide 2 Magnetic Resonance Spectroscopy 2 LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 2 Androgen Antagonists 2 Abiraterone Acetate 2 darolutamide 1 apalutamide 1 abiraterone 1 Watchful Waiting 1 Urination 1 Ultrasound, High-Intensity Focused, Transrectal 1 Transurethral Resection of Prostate 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Single Photon Emission Computed Tomography Computed Tomography 1 Rehabilitation 1 Radiotherapy 1 Radiosurgery 1 Prednisone 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Multiparametric Magnetic Resonance Imaging 1 Metformin 1 Magnetic Resonance Imaging 1 Finasteride 1 Everolimus 1 Dutasteride 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting

11,992 enrolled

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡